Abstract:5AMP-activated protein kinase (AMPK) activators show potential for treating Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) due to their inhibiting effects on fatty acid and cholesterol synthesis. The absence of treatments for NASH, and its propensity for progression to severe disease, lead us to identify and characterize BI9774, a small molecule AMPK activator, which we used to evaluate this potential, including its ability to reduce the NASH specific qualities of fibrosis and inflammation in a preclinical study. Male Lepob/Lepob mice on a control or NASH inducing (AMLN) diet, with liver fibrosis were given BI9774 or vehicle for 6 weeks while metabolic and NASH endpoints were evaluated. BI9774 treatment decreased plasma ALT, terminal liver weight, and liver lipids. RNA expression of collagen-related genes decreased, although collagen protein and inflammation remained unaltered. We also observed increased heart weight and glycogen levels, and increased expression of genes associated with cardiac hypertrophy. AMPK activation improved many metabolic endpoints, but lack of significant improvement in liver fibrosis and negative cardiac effects suggest systemic AMPK activation is not an ideal NASH therapy. Reductions in steatosis and fibrosis-related genes indicate that, with extended treatment, a liver specific AMPK activator has potential to resolve hepatic fibrosis.

What problem does this paper attempt to address?

The paper attempts to address the treatment of non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). Specifically, the researchers aim to reduce liver fat accumulation (steatosis) by activating 5' AMP-activated protein kinase (AMPK) and to explore its effects on liver fibrosis. ### Main Issues: 1. **Reducing liver fat accumulation**: A major characteristic of NAFLD and NASH is the abnormal accumulation of fat in the liver, which can lead to impaired liver function. The researchers aim to verify whether AMPK activation can effectively reduce this fat accumulation. 2. **Improving liver fibrosis**: While reducing fat accumulation is important, a more severe issue in NASH is the formation of liver fibrosis, which can lead to cirrhosis and liver cancer. The researchers hope to assess the impact of AMPK activation on fibrosis. 3. **Evaluating the safety and efficacy of systemic AMPK activation**: Due to the current lack of effective treatments for NASH, the researchers aim to evaluate the safety and potential efficacy of systemic AMPK activation in animal models. ### Research Background: - **Prevalence of NAFLD and NASH**: NAFLD is the most common chronic liver disease worldwide, affecting about 25% of adults. Approximately 30% of these patients will progress to NASH, which can further develop into cirrhosis and liver cancer. - **Role of AMPK**: AMPK is a key regulator of energy balance, and its activation can inhibit the synthesis of fatty acids and cholesterol, potentially aiding in the treatment of metabolic diseases, including NAFLD and NASH. ### Research Methods: - **Animal model**: The researchers used a specific transgenic mouse model (Lepob/Lepob), which develops pathological features similar to human NASH when fed a high-fat, high-fructose, high-cholesterol diet. - **Drug intervention**: The researchers used a small molecule AMPK activator called BI9774, administered orally, to evaluate its effects on liver fat accumulation and fibrosis. ### Research Results: - **Reduction in liver fat accumulation**: BI9774 significantly reduced liver weight and liver fat content, indicating that AMPK activation can effectively reduce liver fat accumulation. - **Limited impact on fibrosis**: Although BI9774 reduced the expression of genes associated with fibrosis, no significant histological improvement in fibrosis was observed. - **Cardiac effects**: BI9774 also led to increased heart weight and myocardial glycogen storage, which may be adverse side effects of AMPK activation. ### Conclusion: - **Efficacy of AMPK activation**: Systemic activation of AMPK can significantly reduce liver fat accumulation, but its effect on improving fibrosis is limited. - **Safety concerns**: AMPK activation may cause adverse side effects such as cardiac hypertrophy, necessitating further research to optimize treatment strategies, such as developing liver-specific AMPK activators or adjusting dosages. Overall, this study provides important data on AMPK as a therapeutic target for NASH but also highlights potential safety issues, guiding further research directions.

Direct β1/β2 AMPK activation reduces liver steatosis but not fibrosis in a mouse model of non-alcoholic steatohepatitis

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD

Discovery of a natural small-molecule AMP-activated kinase activator that alleviates nonalcoholic steatohepatitis

AMPK-activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching

Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs–EBP interaction recover NAFLD through enhancing mitochondrial function in mice

NSC48160 Targets AMPKα to Ameliorate Nonalcoholic Steatohepatitis by Inhibiting Lipogenesis and Mitochondrial Oxidative Stress

Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

LB100 Ameliorates Nonalcoholic Fatty Liver Disease Via the AMPK/Sirt1 Pathway.

AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development

LRG Ameliorates Steatohepatitis by Activating the AMPK/mTOR/SREBP1 Signaling Pathway in C57BL/6J Mice Fed a High‑fat Diet.

α,β-Amyrin prevents steatosis and insulin resistance in a high-fat diet-induced mouse model of NAFLD via the AMPK-mTORC1-SREBP1 signaling mechanism

AMPKα1 Overexpression Alleviates the Hepatocyte Model of Nonalcoholic Fatty Liver Disease Via Inactivating P38mapk Pathway.

Pharmacological Activation of AMPK Prevents Drp1-mediated Mitochondrial Fission and Alleviates Hepatic Steatosis In vitro

AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model

Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway

Activation of AMPK pathway by low‐dose donafenib and atorvastatin combination improves high‐fat diet‐induced metabolic dysfunction‐associated steatotic liver disease

Potent Efficacy of 3-Amino-4-hydroxy Benzoic Acid, a Small Molecule Having Anti-fibrotic Activity, in a Mouse Model of Non-alcoholic Steatohepatitis

Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH liver disease

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis